Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT07480356, led by Protara Therapeutics, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Randomised Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-Grade Non-Muscle Invasive Bladder Cancer. Planned enrolment is 284 participants (estimated). The study started in 2026-05-29 and primary completion is expected in 2028-04. No results have been posted on ClinicalTrials.gov.